Take this benchmark to assess how much you would benefit from taking the course on Compliance and Implementation of the FDA Final Rule on Reclassification of Hepatitis B Virus (HBV) Assay Devices. In a few minutes, you’ll see how well you understand the rule’s intent, who it impacts, and what it asks you to do.
What you’ll get:
– A quick read on your grasp of five areas: policy intent, operational impact, equity/access implications, program philosophy, and practical readiness
– Insight into trade-offs you’ll need to manage (e.g., speed to market vs. safety guardrails; flexibility vs. compliance)
– Clear signals on where the course can save you time and reduce risk (special controls, 510(k) strategy, labeling, PCCPs, and postmarket obligations)
Who should take this benchmark:
– Anyone touching HBV assays—manufacturing, regulatory, quality, clinical/lab operations, product, and compliance teams
How to use your results:
– Many correct responses: you likely need targeted refreshers
– Mixed results: the full course will help you translate requirements into action
– Mostly incorrect: start with policy intent and special controls, then move to 510(k), labeling, and change management
The goal: make it obvious whether this training will accelerate your submissions, strengthen compliance, and improve patient access—before you invest more time.



